AbbVie's Allergan Aesthetics unit unveiled positive Phase 4 data at ASDS 2026, demonstrating that multimodal aesthetic treatments significantly improve facial satisfaction and skin quality for patients using GLP-1 weight-loss medications.
Allergan Aesthetics, an AbbVie company, presented positive Phase 4 data at ASDS 2026 (Nov. 5-8): a 42.4-point FACE-Q improvement in the 30-person HARMONY IN DIVERSITY GLP-1 cohort and 95.7% satisfaction in the 25-person HALO interim analysis. These are small patient-satisfaction studies supporting the aesthetics franchise, but they carry no revenue figures, guidance change or regulatory approval, so the price effect is routine at most.
Allergan Aesthetics, an AbbVie company, presented Phase 4 study results at the 2026 ASDS Annual Meeting showing improved patient satisfaction for those on GLP-1 medications. The HARMONY IN DIVERSITY study reported a 42.4-point improvement in facial appearance satisfaction, while the HALO interim analysis indicated 95.7% participant satisfaction with HA injectable treatments.
People taking GLP-1 medications for weight loss may experience facial volume loss and skin-quality changes, creating demand for AbbVie's neurotoxins, hyaluronic acid injectables and skincare, per the studies presented.